↓ Skip to main content

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

Overview of attention for article published in BMC Musculoskeletal Disorders, May 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)

Mentioned by

twitter
10 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study
Published in
BMC Musculoskeletal Disorders, May 2014
DOI 10.1186/1471-2474-15-177
Pubmed ID
Authors

Charles H Pritchard, Maria W Greenwald, Joel M Kremer, Norman B Gaylis, William Rigby, Steve Zlotnick, Carol Chung, Birgit Jaber, William Reiss

Abstract

As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safety of infusing rituximab at a faster rate for an infusion period of 2 hours in patients with RA.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Colombia 1 3%
Unknown 37 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 21%
Researcher 7 18%
Student > Ph. D. Student 5 13%
Student > Bachelor 4 10%
Other 4 10%
Other 5 13%
Unknown 6 15%
Readers by discipline Count As %
Medicine and Dentistry 17 44%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Agricultural and Biological Sciences 2 5%
Immunology and Microbiology 2 5%
Psychology 2 5%
Other 4 10%
Unknown 8 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2014.
All research outputs
#5,459,127
of 21,343,339 outputs
Outputs from BMC Musculoskeletal Disorders
#1,002
of 3,772 outputs
Outputs of similar age
#49,759
of 205,050 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#1
of 1 outputs
Altmetric has tracked 21,343,339 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 3,772 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 205,050 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them